Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Accumulated Expenses: 2010-2025

Historic Accumulated Expenses for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Sep 2025 value amounting to $34.6 million.

  • Ironwood Pharmaceuticals' Accumulated Expenses rose 3.14% to $34.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.6 million, marking a year-over-year increase of 3.14%. This contributed to the annual value of $26.8 million for FY2024, which is 39.33% down from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Accumulated Expenses stood at $34.6 million, which was up 44.05% from $24.0 million recorded in Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Accumulated Expenses peaked at $79.6 million during Q2 2023, and registered a low of $13.4 million during Q2 2022.
  • For the 3-year period, Ironwood Pharmaceuticals' Accumulated Expenses averaged around $38.2 million, with its median value being $33.4 million (2025).
  • In the last 5 years, Ironwood Pharmaceuticals' Accumulated Expenses surged by 492.81% in 2023 and then tumbled by 59.28% in 2024.
  • Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' Accumulated Expenses stood at $23.6 million in 2021, then declined by 29.14% to $16.7 million in 2022, then skyrocketed by 164.99% to $44.3 million in 2023, then tumbled by 39.33% to $26.8 million in 2024, then increased by 3.14% to $34.6 million in 2025.
  • Its last three reported values are $34.6 million in Q3 2025, $24.0 million for Q2 2025, and $33.4 million during Q1 2025.